Equities Analysts Offer Predictions for IONS FY2028 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Analysts at William Blair dropped their FY2028 earnings per share estimates for Ionis Pharmaceuticals in a report released on Friday, December 20th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of $2.07 for the year, down from their prior estimate of $2.26. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.37) per share.

Several other brokerages have also recently commented on IONS. Wells Fargo & Company lowered their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a report on Thursday, November 7th. StockNews.com downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, November 12th. Royal Bank of Canada restated an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday. Finally, JPMorgan Chase & Co. raised their target price on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a "neutral" rating in a report on Monday, August 26th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $60.65.

Ionis Pharmaceuticals Stock Performance

Ionis Pharmaceuticals stock traded up $0.45 during midday trading on Monday, hitting $36.08. The company's stock had a trading volume of 1,816,073 shares, compared to its average volume of 1,357,089. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The company has a market cap of $5.70 billion, a price-to-earnings ratio of -14.79 and a beta of 0.35. Ionis Pharmaceuticals has a 1-year low of $33.33 and a 1-year high of $54.44. The company has a 50-day moving average price of $37.33 and a two-hundred day moving average price of $42.26.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the sale, the executive vice president now owns 33,713 shares of the company's stock, valued at approximately $1,278,396.96. This represents a 3.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 6,630 shares of the business's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the transaction, the chief executive officer now owns 167,393 shares in the company, valued at $6,369,303.65. This trade represents a 3.81 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,877 shares of company stock valued at $299,578. Insiders own 2.71% of the company's stock.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Ionis Pharmaceuticals by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company's stock worth $106,922,000 after acquiring an additional 183,814 shares during the period. Great Point Partners LLC acquired a new stake in Ionis Pharmaceuticals during the second quarter worth approximately $15,728,000. Charles Schwab Investment Management Inc. increased its holdings in Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company's stock worth $57,807,000 after purchasing an additional 114,914 shares in the last quarter. DRW Securities LLC acquired a new position in Ionis Pharmaceuticals in the second quarter valued at approximately $2,429,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 13.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 650,779 shares of the company's stock worth $26,070,000 after buying an additional 77,909 shares in the last quarter. Institutional investors own 93.86% of the company's stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.